RNA cleavage and inhibition of protein synthesis by Bleomycin

Chemistry and Biology

Volumn 10, Issue 1, 2003, Pages 45-52

  Abraham, Anil T ^a   Lin, Jih Jing ^b   Newton, Dianne L ^c   Rybak, Susanna ^b   Hecht, Sidney M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0037259429     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(02)00306-X     Document Type: Article

References (51)

1. Sikic B.I., Rozencweig M., Carter S.K. Bleomycin Chemotherapy. 1985;Academic Press, Orlando, FL.
2. Natrajan A., Hecht S.M. In Molecular Aspects of Anticancer Drug-DNA Interactions. S. Neidle and M. Waring. 1993;MacMillan, London. 197-242.pp.
3. Hecht, S.M. (1995). In Cancer Chemotherapeutic Agents, W.O. Foye, ed. (Washington, DC: American Chemical Society), pp. 369-388.
4. Burger R.M. Cleavage of nucleic acids by bleomycin. Chem. Rev. 98:1998;1153-1169.
5. Magliozzo R.S., Peisach J., Ciriolo M.R. Transfer-RNA is cleaved by activated bleomycin. Mol. Pharmacol. 35:1989;428-432.
6. Carter B.J., deVroom E., Long E.C., van der Marel G.A., van Boom J.H., Hecht S.M. Site-specific cleavage of RNA by Fe(III)•bleomycin. Proc. Natl. Acad. Sci. USA. 87:1990;9373-9377.
7. Hecht S.M. RNA degradation by bleomycin. Bioconjug. Chem. 5:1994;513-526.
8. Hecht, S.M. (1998). In The Many Faces of RNA, D.S. Eggleston, C.D. Prescott, and N.D. Pearson, eds. (San Diego, CA: Academic Press), pp. 3-17.
9. Ardelt W., Mikulski S.M., Shogen K. Amino-acid-sequence of an antitumor protein from rana-pipiens oocytes and early embryos-homology to pancreatic ribonucleases. J. Biol. Chem. 266:1991;245-251.
10. Darzynkiewicz Z., Carter S.P., Mikulski S.M., Ardelt W.J., Shogen K. Cytostatic and cyto-toxic effects of pannon P-30. A novel anticancer agent. Cell Tissue Kinet. 21:1988;169-182.
11. Mikulski S.M., Viera A., Ardelt W., Menduke H., Shogen K. Tamoxifen and trifluoroperazine (stelazine) potentiate cytostatic cytotoxic effects of P-30 protein. A novel protein possessing antitumor-activity. Cell Tissue Kinet. 23:1990;237-246.
12. Mikulski S.M., Ardelt W., Shogen K., Bernstein E.H., Menduke H. Striking increase of survival of mice bearing M109 madison carcinoma treated with a novel protein from amphibian embryos. J. Natl. Cancer Inst. 82:1990;151-153.
13. Mikulski S.M., Grossman A.M., Carter P.W., Shogen K., Costanzi J.J. Phase-I human clinical-trial of onconase (R) (P-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors. Int. J. Oncol. 3:1993;57-64.
14. Grever M.R., Schepartz S.A., Chabner B.A. The National Cancer Institute cancer drug discovery and development program. Semin. Oncol. 19:1992;622-638.
15. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A.et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:1991;757-766.
16. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines-development of mean graph and compare algorithm. J. Natl. Cancer Inst. 81:1989;1088-1092.
17. Lee-Huang S., Huang P.L., Nara P.L., Chen H.C., Kung H.F., Huang P., Huang H.I., Huang P.L. MAP-30-a new inhibitor of HIV-1 infection and replication. FEBS Lett. 272:1990;12-18.
18. Conde F.P., Fernandez-Puentes C., Montero M.T.V., Vazquez D. Protein toxins that catalytically inactivate ribosomes from Eukaryotic organisms. Studies on the mode of action of α-sarchin mytogellin and restrictocin response to α-sarcin antibodies. FEMS Microbiol. Lett. 4:1978;349-355.
19. Lin J.J., Newton D.L., Mikulski S.M., Kung H.F., Youle R.J., Rybak S.M. Characterization of the mechanism of cellular-free protein-synthesis inhibition by an antitumor ribonuclease. Biochem. Biophys. Res. Commun. 204:1994;156-162.
20. Wu Y.N., Mikulski S.M., Ardelt W., Rybak S.M., Youle R.J. A cytotoxic ribonuclease study of the mechanism of onconase cytotoxicity. J. Biol. Chem. 268:1993;10686-10693.
21. Iordanov M.S., Ryabinina O.P., Wong J., Dinh T.H., Newton D.L., Rybak S.M., Magun B.E. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase. Evidence for cytotoxic mechanism different from inhibition of protein synthesis. Cancer Res. 60:2000;1983-1994.
22. Skehan P., Storeng R., Scudiero D.A., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
23. Saxena S.K., Rybak S.M., Davey R.T., Youle R.J., Ackerman E.J. Angiogenin is a cytotoxic transfer RNA-specific ribonuclease in the RNAse A superfamily. J. Biol. Chem. 267:1992;21982-21986.
24. Rybak S.M., Saxena S.K., Ackerman E.J., Youle R.J. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J. Biol. Chem. 266:1991;21202-21207.
25. Fett J.W., Strydom D.J., Lobb R.R., Alderman E.M., Bethune J.L., Riordan J.F., Vallee B.L. Isolation and characterization of angiogenin, and angiogenic protein from human carcinoma cells. Biochemistry. 24:1985;5480-5486.
26. Shapiro R., Strydom D.J., Olson K.A., Vallee B.L. Isolation of angiogenin from normal human-plasma. Biochemistry. 26:1987;5141-5146.
27. Chaconas G., Van de Sande J.H., Church R.B. End group labeling of RNA and double stranded DNA by phosphate exchange catalyzed by bacteriophage T4 induced polynucleotide kinase. Biochem. Biophys. Res. Commun. 66:1975;962-969.
28. Koutsoukos A.D., Rubinstein L.V., Faraggi D., Simon R.M., Kalyandrug S., Weinstein J.N., Kohn K.W., Paull K.D. Discrimination techniques applied to the NCI in vitro antitumor drug screen prediciting biochemical mechanism of action. Stat. Med. 13:1994;719-730.
29. Suzuki H., Nagai K., Akutsu E., Yamaki T., Tanaka N., Umezawa H. On the mechanism of action of bleomycin. strand scission of DNA caused by bleomycin and its binding to DNA in vitro J. Antibiot. (Tokyo). 23:1970;473-480.
30. Müller W.E.G., Yamazaki Z., Breter H.-J., Zahn R.K. Action of bleomycin on DNA and RNA. Eur. J. Biochem. 31:1972;518-525.
31. Haidle C.W., Kuo M.T., Weiss K.K. Nucleic-acid specificity of bleomycin. Biochem. Pharmacol. 21:1972;3308-3312.
32. Hori, M. (1979). In Bleomycin: Chemical Biochemical and Biological Aspects, S.M. Hecht, ed. (New York: Springer-Verlag), pp. 195-206.
33. Phe mediated by metal free bleomycin. Biochemistry. 34:1995;12029-12037.
34. Colman, A. (1984). In Transcription and Translation: A Practical Approach, B.D. James and S.J. Higgins, eds. (Oxford: IRL Press), pp. 49-69.
35. Nakamura M., Peisach J. Self-inactivation of Fe(II)-bleomycin. J. Antibiot. (Tokyo). 41:1988;638-647.
36. Van Atta R.B., Long E.C., Hecht S.M. Electrochemical activation of oxygenated Fe-bleomycin. J. Am. Chem. Soc. 111:1989;2722-2724.
37. Owa T., Sugiyama T., Otsuka M., Ohno M., Maeda K. Synthetic studies of antitumor antibiotic bleomycin 30. A model study on the mechanism of the autoxidation of bleomycin. Tetrahedron Lett. 31:1990;6063-6066.
38. Rybak S.M., Vallee B.L. Base cleavage specificity of angiogenin with saccharomyces-cerevisiae and escherichia coli 5S-RNAs. Biochemistry. 27:1988;2288-2294.
39. Huttenhofer A., Hudson S., Noller H.F., Mascharak P.D. Cleavage of transfer RNA by Fe(II)-bleomycin. J. Biol. Chem. 267:1992;2471-2475.
40. Holmes C.E., Carter B.J., Hecht S.M. Characterization of iron(III)-bleomycin-mediated RNA strand scission. Biochemistry. 32:1993;4293-4307.
41. Ehrenfeld G.M., Shipley J.B., Heimbrook D.C., Sugiyama H., Long E.C., van Boom J.H., van der Marel G.A., Oppenheimer N.J., Hecht S.M. Copper dependent cleavage of DNA by bleomycin. Biochemistry. 26:1987;931-942.
42. Poddevin B., Orlowski S., Belehradek J. Jr., Mir L.M. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem. Pharmacol. 42:1991;S67-S75.
43. Ogawa T., Tomita K., Ueda T., Watanabe K., Uozumi T., Masaki H. A cytotoxic ribonuclease targeting specific transfer RNA anticodons. Science. 283:1999;2097-2100.
44. Tomita K., Ogawa T., Uozumi T., Watanabe K., Masaki H. A cytotoxic ribonuclease which specifically cleaves four isoaccepting arginine tRNAs at their anticodon loops. Proc. Natl. Acad. Sci. USA. 97:1999;8278-8283.
45. Ruller S., Stahl C., Kohler G., Eickhoff B., Breder J., Schlaak M., van der Bosch J. Sensitization of tumor cells to ribotoxic stress-induced apoptotic cell death. a new therapeutic strategy Clin. Cancer Res. 5:1999;2714-2725.
46. Chien M., Grollman A.P., Horwitz S.B. Bleomycin-DNA interactions. fluorescence and proton magnetic resonance studies Biochemistry. 16:1977;3641-3646.
47. St. Clair D.K., Rybak S.M., Riordan J.F., Vallee B.L. Angiogenin abolishes cell-free protein synthesis by specific ribonucleolytic inactivation of ribosomes. Proc. Natl. Acad. Sci. USA. 84:1987;8330-8334.
48. Gurdon J. Methods for nuclear transplantation in amphibia. Methods Cell Biol. 16:1977;125-139.
49. Melton D.A. Injected anti-sense RNAs specifically block messenger RNA translation in vivo. Proc. Natl. Acad. Sci. USA. 82:1985;144-148.
50. Saxena S.K., Rybak S.M., Winkler G., Meade H.M., McGray P., Youle R.J., Ackerman E.J. Comparison use of immunotoxins-monoclonal-antibodies conjugated to protein toxins. J. Biol. Chem. 266:1991;21208-21214.
51. Maniatis T., Fritsch E.F., Sambrook J. Molecular Cloning. A Laboratory Manual:1982;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.